Skip to content
TrialScanner

NCT03459079

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Phase 2CompletedIVACollaborator

Registry record

Lead sponsor
University of Florida
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD); Type 2 Diabetes (T2DM)
Primary completion
Apr 18, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03459079 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03459079: Lanifibranor in Patients... | TrialScanner